SCHEMBL6529330

SCHEMBL6529330

NC(=O)c1cn(C2CCCCC2)c(OCCO)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TGFBR1 P36897 2/20 0.35
PRKD1 Q15139 1/20 0.35
OPRM1 P35372 2/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
PLK1 P53350 1/20 0.33
PLK3 Q9H4B4 1/20 0.33
PLK2 Q9NYY3 1/20 0.33
KCNH2 Q12809 1/20 0.33
TGFBR2 P37173 1/20 0.33
BTK Q06187 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 1/20 0.33
PARP15 Q460N3 1/20 0.33
PARP10 Q53GL7 1/20 0.33
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6529327 0.78 MEN1 (0.36) MEN1KMT2APRKD1OPRM1
SCHEMBL19691308 0.68 PRKD1 (0.35) MEN1KMT2APRKD1OPRM1KCNH2
SCHEMBL6504137 0.66 CPB2 (0.47) MEN1KMT2AHSD17B10GAA
SCHEMBL3081873 0.62 PARP10 (0.38) MEN1KMT2AKCNH2PARP15PARP10
SCHEMBL18850919 0.62 PSMB8 (0.54) MEN1KMT2ABTK
SCHEMBL6692541 0.62 TDP1 (0.48) TGFBR1TGFBR2HSD17B10GAA
SCHEMBL18850877 0.62 PSMB8 (0.54) MEN1KMT2ABTK
SCHEMBL6305633 0.62 KCNH2 (0.42) OPRM1KCNH2GAA
SCHEMBL4803883 0.61 HCAR2 (0.36) HSD17B10GAA
SCHEMBL2364931 0.60 LMNA (0.41) MEN1KMT2ATGFBR1PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256167-A1 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256167-A1 Preparation and use of imidazole derivatives for treatment of obesity GPR119, GIPR, PGC MEN1 1397/4885KMT2A 481/4885TGFBR1 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.